Cargando…

A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for non-small cell lung cancer (NSCLC) with EGFR mutations. Approximately half of the patients with EGFR-mutated NSCLC are treated with EGFR-TKIs and develop disease progression within...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Chia-Feng, Liao, Chien-Yi, Chao, Heng-Sheng, Chiu, Hwa-Yen, Wang, Ting-Wei, Lee, Yen, Chen, Jyun-Ru, Shiao, Tsu-Hui, Chen, Yuh-Min, Wu, Yu-Te
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854198/ https://www.ncbi.nlm.nih.gov/pubmed/36670497 http://dx.doi.org/10.1186/s40644-023-00522-5

Ejemplares similares

Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors
por: Wang, Ting-Wei, et al.
Publicado: (2023)

Evaluating the Potential of Delta Radiomics for Assessing Tyrosine Kinase Inhibitor Treatment Response in Non-Small Cell Lung Cancer Patients
por: Wang, Ting-Wei, et al.
Publicado: (2023)

Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Ting-Wei, et al.
Publicado: (2023)

Radiomics-Based Deep Learning Prediction of Overall Survival in Non-Small-Cell Lung Cancer Using Contrast-Enhanced Computed Tomography
por: Hou, Kuei-Yuan, et al.
Publicado: (2022)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

Clinical Characteristics of Rapid Eye Movement-Related Obstructive Sleep Apnea: An Experience in a Tertiary Medical Center of Taiwan
por: Chiu, Hwa-Yen, et al.
Publicado: (2022)

Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations
por: Tu, Chih-Yen, et al.
Publicado: (2018)

NEAP/DUSP26 suppresses receptor tyrosine kinases and regulates neuronal development in zebrafish
por: Yang, Chi-Hwa, et al.
Publicado: (2017)

Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma
por: Chen, Hung-Jen, et al.
Publicado: (2020)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Obstructive sleep apnea in young Asian adults with sleep-related complaints
por: Chiu, Hwa-Yen, et al.
Publicado: (2022)

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
por: Su, Vincent Yi-Fong, et al.
Publicado: (2020)

Artificial Intelligence for Early Detection of Chest Nodules in X-ray Images
por: Chiu, Hwa-Yen, et al.
Publicado: (2022)

Application of Artificial Intelligence in Lung Cancer
por: Chiu, Hwa-Yen, et al.
Publicado: (2022)

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
por: Hsia, Te‐Chun, et al.
Publicado: (2018)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
por: Masbuchin, Ainun Nizar, et al.
Publicado: (2022)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Clinical-radiomic model in advanced kidney cancer predicts response to tyrosine kinase inhibitors
por: Negreros-Osuna, Adrián A., et al.
Publicado: (2022)

Anchor-based classification and type-C inhibitors for tyrosine kinases
por: Hsu, Kai-Cheng, et al.
Publicado: (2015)

Overview of coronavirus disease 2019: Treatment updates and advances
por: Luo, Yung-Hung, et al.
Publicado: (2020)

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
por: Shen, Chia-I, et al.
Publicado: (2021)

Impaired Liver Function Implied Shorter Progression Free Survival for EGFR Tyrosine Kinase Inhibitors
por: Zhu, Qi-Qi, et al.
Publicado: (2018)

Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
por: Chou, Wen-Ru, et al.
Publicado: (2022)

Cell-free expression of functional receptor tyrosine kinases
por: He, Wei, et al.
Publicado: (2015)

Radiomic features analysis in computed tomography images of lung nodule classification
por: Chen, Chia-Hung, et al.
Publicado: (2018)

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
por: Kim, Hyungjin, et al.
Publicado: (2017)

Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance
por: Ng, Yen-Shing, et al.
Publicado: (2004)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

Radiomic Feature-Based Nomogram: A Novel Technique to Predict EGFR-Activating Mutations for EGFR Tyrosin Kinase Inhibitor Therapy
por: Weng, Qiaoyou, et al.
Publicado: (2021)

EGFR Tyrosine Kinase Inhibitor–Associated Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic
por: Chang, Hsu-Liang, et al.
Publicado: (2020)

Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non–Small Cell Lung Cancer in Taiwan
por: Chang, Wei-Ting, et al.
Publicado: (2023)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Kim, Yundeok, et al.
Publicado: (2021)

Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
por: Cortes, Jorge, et al.
Publicado: (2018)

Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations
por: Sandoval-Pérez, Angélica, et al.
Publicado: (2022)

Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells
por: Wu, Wen-Shin, et al.
Publicado: (2016)

Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result
por: Chen, Yuntian, et al.
Publicado: (2023)

Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

TYRO protein tyrosine kinase-binding protein predicts favorable overall survival in osteosarcoma and correlates with antitumor immunity
por: Xu, Hai-Ru, et al.
Publicado: (2022)

Computational Study of the “DFG-Flip” Conformational Transition in c-Abl and c-Src Tyrosine Kinases
por: Meng, Yilin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_d1flno6qot7n0vlb4bjcbeml1g